The results come from a phase 3 trial of the vaccine – known as BNT162b2 – in adolescents aged 12 to 15 years old, with or without prior evidence of SARS-CoV-2 infection.
In this population, the vaccine – in addition to demonstrating 100% efficacy – also produced robust antibody responses, which exceeded those recorded earlier in vaccinated participants aged 16 to 25 years old according to the companies.
Pfizer and BioNTech added that the vaccine was also well tolerated, with side effects ‘generally consistent’ with those seen in participants aged 16 to 25 years.
“Across the globe, we are longing for a normal life. This is especially true for our children,” said Ugur Sahin, chief executive officer and co-founder of BioNTech…